Article citationsMore>>

D. H. Brewster, L. A. Bhatti, J. H. C. Inglis, E. R. Nairn and V. R. Doherty, “Recent Trends in Incidence of Nonmelanoma Skin Cancers in the East of Scotland, 19922003,” British Journal of Dermatology, Vol. 156, No. 6, 2007, pp. 1295-1300. doi:10.1111/j.1365-2133.2007.07892.x

has been cited by the following article:

• TITLE: Topical CuradermBEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes

  AUTHORS: Bill E. Cham

  KEYWORDS: Periocular Skin Cancers; CuradermBEC5; Apoptosis; Solamargine; Basal Cell Carcinoma; Squamous Cell Carcinoma; Cosmesis; Solanum

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.4 No.5, May 16, 2013

  ABSTRACT: Approximately 5 to 10 percent of all skin cancers occur in the periocular region. Basal cell carcinoma is the most frequent malignant periocular tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Nonmelanoma skin tumors at the periocular area often cause disfigurement with destruction of soft conjunctival tissue. Many therapeutic methods have been recommended to combat the morbidity and mortality associated with these lesions. Excisions with frozen-section control or Mohs micrographic surgery are regarded as the gold-standard treatments for periocular basal cell and squamous cell carcinomas. However, these treatment modalities have various limitations and reconstruction surgery is often associated with these treatment options. The chemotherapeutic agents solasodine rhamnosides in a cream formulation CuradermBEC5 are specific, effective and safe treatments for nonmelanoma skin cancers with excellent cosmesis. The antineoplastic mode of action is by apoptosis. In this review it is shown that CuradermBEC5 also treats periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no reconstructive surgery is required.